Want to see GB:PRTC full AI Analyst Report?
Top Page
PureTech Health
(LSE:PRTC)
Select Model
Select Model
Rating:50Neutral
Price Target:
117.00 p
▼(-4.41% Downside)
Action:Reiterated
Date:08/07/26
The score is held back primarily by weak financial performance (large losses and persistent cash burn) and bearish technical trends (below key moving averages with negative MACD). Partially offsetting this are a relatively strong balance sheet and a constructive earnings call that emphasized extended runway, improved operating loss, and clinical/portfolio progress, though funding and execution risks remain material.
Positive Factors
Balance Sheet and Runway
Substantial liquidity and limited leverage provide time to advance clinical programs without immediate balance-sheet stress. Runway through 2028 supports portfolio development, although continued spending means this cushion will gradually decline.
Negative Factors
Persistent Cash Burn
Sustained negative cash generation means PureTech must fund operations from existing reserves, asset monetizations or external capital. Even with improved burn versus 2024, prolonged development spending can shrink financial flexibility and increase financing dependence.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet and Runway
Substantial liquidity and limited leverage provide time to advance clinical programs without immediate balance-sheet stress. Runway through 2028 supports portfolio development, although continued spending means this cushion will gradually decline.
Read all positive factors
PureTech Health (PRTC) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£298.14M
Dividend YieldN/A
Average Volume (3M)825.77K
Price to Earnings (P/E)―
Beta (1Y)1.36
Revenue Growth-5.89%
EPS Growth-310.69%
CountryUK
Employees56
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.46
Shares Outstanding245,179,640
10 Day Avg. Volume1,092,790
30 Day Avg. Volume825,768
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.30
Price to Sales (P/S)85.14
P/FCF Ratio-4.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£508.00Price Target Upside315.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.46
Revenue Forecast (FY)£11.50M
PureTech Health Business Overview & Revenue Model
Company Description
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neu...
How the Company Makes Money
PureTech Health primarily makes money through (1) value creation and monetization of its equity stakes in affiliated companies it has founded or backed (e.g., proceeds from public listings, sales of shares, or other liquidity events), and (2) paym...
PureTech Health Earnings Call Summary
Earnings Call Date:Apr 29, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Sep 22, 2026
Earnings Call Sentiment Positive
The call presented meaningful operational and clinical progress — notably positive Phase Ib data for Gallop (LYT‑200), Celea Phase IIb success and Phase III readiness, Seaport IPO momentum, improved operating loss and a confirmed runway through end‑2028 — while also acknowledging near‑term financial headwinds including a year‑over‑year cash decline, a swing to net loss driven by the absence of a one‑time 2024 gain, modest revenue, and the need for substantial external capital to fund late‑stage programs. Management emphasized capital discipline, earlier capitalization of founded entities, and intention to return cash to shareholders, but execution of financings (Celea, Gallop) and sensitivity to early product sales (Cobenfy) remain material risks.Positive Updates
Positive Gallop (LYT-200) Phase Ib Results
Top-line Phase Ib data showed an excellent safety profile (no dose-limiting toxicities or myeloid suppression), dose-dependent efficacy and identification of 12 mg/kg as the dose for next study. PureTech will prioritize relapsed/refractory high-risk MDS, plans FDA engagement for a potentially registration-enabling trial, and intends to seek majority third-party capital to fund next-stage development.
Negative Updates
Year‑over‑Year Cash Decline
PureTech-level cash fell from $366.8M at end-2024 to $277.1M at end-2025, a decline of $89.7M (≈24.5%). Consolidated cash moved similarly (≈24.5% decline). Unaudited Q1 2026 cash was ~$248.1M (≈10.5% decrease from end-2025).
Read all updates
Q4-2025 Updates
Positive
Negative
Positive Gallop (LYT-200) Phase Ib Results
Top-line Phase Ib data showed an excellent safety profile (no dose-limiting toxicities or myeloid suppression), dose-dependent efficacy and identification of 12 mg/kg as the dose for next study. PureTech will prioritize relapsed/refractory high-risk MDS, plans FDA engagement for a potentially registration-enabling trial, and intends to seek majority third-party capital to fund next-stage development.
Read all positive updates
Company Guidance
Management reiterated conservative financial guidance and operational priorities: PureTech-level cash and cash equivalents were $277.1M at 31‑Dec‑2025 and $248.1M (unaudited) at 31‑Mar‑2026 (consolidated $277.3M and $248.2M), and the company expects operational runway at least through end‑2028 inclusive of planned participation in founded‑entity fundraises; 2025 consolidated revenue was $4.7M (vs $4.8M in 2024), operating loss $98.5M (vs $136.1M in 2024) and consolidated net loss $110.1M (2024 included a $151.8M one‑time gain), while PureTech has received ~$125M from prior royalty monetization, cites ~ $160M projected value of Cobenfy economics through 2033 (analyst consensus) and says it has generated over $1B from monetizations to date. On R&D and portfolio metrics, management expects to progress up to three concept‑stage programs and nominate up to two development candidates over the next three years, will target closing Celea financing to support the Phase III SURPASS‑IPF by early Q3‑2026 (with trial to begin close to close), and for Gallop selected a 12 mg/kg dose for LYT‑200 and will pursue a potentially registration‑enabling trial in relapsed/refractory high‑risk MDS (100% of MDS patients in the Phase Ib had prior HMA; historical response after HMA failure 0–5%; TIBSOVO addresses ~3–5% of patients).PureTech Health Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
70
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.76M | 4.32M | 750.00K | 2.09M | 9.98M |
| Gross Profit | 1.34M | 4.32M | -92.91M | -136.81M | -100.49M |
| EBITDA | -97.17M | 37.38M | -17.68M | -79.94M | -46.95M |
| Net Income | -112.04M | 53.51M | -65.70M | -50.35M | -60.56M |
Balance Sheet | |||||
| Total Assets | 534.90M | 602.63M | 693.97M | 702.65M | 946.01M |
| Cash, Cash Equivalents and Short-Term Investments | 279.00M | 367.31M | 327.14M | 350.10M | 465.71M |
| Total Debt | 19.76M | 159.14M | 25.34M | 46.87M | 52.75M |
| Total Liabilities | 229.12M | 194.70M | 235.74M | 155.06M | 361.86M |
| Stockholders Equity | 312.19M | 414.71M | 464.07M | 542.22M | 593.51M |
Cash Flow | |||||
| Free Cash Flow | -86.92M | -134.38M | -106.16M | -180.97M | -163.94M |
| Operating Cash Flow | -86.92M | -134.37M | -105.92M | -178.79M | -158.27M |
| Investing Cash Flow | 64.62M | 240.89M | 68.99M | -107.22M | 197.38M |
| Financing Cash Flow | -6.46M | -16.96M | 78.14M | -29.83M | 22.73M |
PureTech Health Technical Analysis
Negative
122.40
Price Trends
121.90
Negative
126.19
Negative
125.54
Negative
Market Momentum
0.45
Negative
50.57
Neutral
57.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PRTC, the sentiment is Negative. The current price of 122.4 is above the 20-day moving average (MA) of 120.38, above the 50-day MA of 121.90, and below the 200-day MA of 125.54, indicating a neutral trend. The MACD of 0.45 indicates Negative momentum. The RSI at 50.57 is Neutral, neither overbought nor oversold. The STOCH value of 57.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:PRTC.
PureTech Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | £115.89M | -18.04 | 90.29% | ― | ― | 69.01% | |
52 Neutral | £316.17M | -7.25 | -2929.47% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £298.14M | -0.60 | -31.83% | ― | -5.89% | -310.69% | |
42 Neutral | £22.46M | -9.73 | -353.21% | 17.86% | ― | 36.67% | |
39 Underperform | £28.88M | 43.47 | 14.26% | ― | ― | ― | |
25 Underperform | £73.55M | -4.36 | -116.21% | ― | 81.46% | -15.88% |
* Healthcare Sector Average
GB:PRTC
PureTech Health
121.60
3.60
3.05%
GB:AVCT
Avacta Group plc
67.50
12.50
22.73%
GB:IMM
ImmuPharma
3.60
-4.46
-55.33%
GB:SCLP
Scancell Holdings
9.56
0.86
9.89%
GB:4BB
4basebio UK Societas
475.00
-380.00
-44.44%
GB:AREC
Arecor Therapeutics PLC
76.50
6.00
8.51%
PureTech Health Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
PureTech updates share capital and voting rights as it emphasizes R&D-driven growth
Positive
Aug 3, 2026
PureTech Health reported that as of 31 July 2026 it had issued 257,927,489 ordinary shares, with 13,552,467 held in treasury, resulting in 244,375,022 voting rights. The disclosure helps investors and other shareholders assess when they must repor...
Executive/Board ChangesRegulatory Filings and Compliance
PureTech Health Awards Vested RSUs to Non-Executive Directors, Updates Share Capital
Neutral
Jul 31, 2026
PureTech Health plc has issued new ordinary shares to several non-executive directors following the full vesting of restricted share units granted under its Performance Share Plan in late 2025. The awards, settled on July 29, 2026, provided each o...
Executive/Board ChangesRegulatory Filings and Compliance
PureTech Health Issues Vested RSU Shares to Senior Executives
Neutral
Jul 17, 2026
PureTech Health has issued ordinary shares to senior executives following the vesting of restricted share units granted under its Performance Share Plan, reflecting a scheduled equity-based compensation event for key management. The awards, net of...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
PureTech’s Celea Starts Landmark Phase 3 Head-to-Head IPF Trial
Positive
Jul 13, 2026
Celea Therapeutics has dosed the first patient in SURPASS-IPF, a global, randomized Phase 3 trial that will directly compare its investigational drug deupirfenidone with established therapy pirfenidone over 52 weeks in approximately 1,100 IPF pati...
Other
PureTech Insiders Boost Holdings with Coordinated Share Purchases
Positive
Jul 9, 2026
PureTech Health reported that several senior insiders, including Chief Executive Officer Robert Lyne and Interim Board Chair Sharon Barber-Lui, purchased ordinary shares on the London Stock Exchange. The transactions, conducted on 7-8 July 2026 at...
Business Operations and StrategyPrivate Placements and Financing
PureTech Spins Out Celea with $180 Million to Advance Phase 3 IPF Drug
Positive
Jul 2, 2026
PureTech Health has launched its founded entity Celea Therapeutics as an independent company and helped it secure $180 million in financing from a syndicate of top-tier healthcare investors. The transaction aligns with PureTech’s strategy of...
Business Operations and StrategyPrivate Placements and Financing
PureTech Spins Out Celea in $180m IPF Bet, Sharpening Lean Portfolio Strategy
Positive
Jul 2, 2026
PureTech Health has launched Celea Therapeutics as an independent, investor-backed entity to advance deupirfenidone, a next-generation antifibrotic aimed at idiopathic pulmonary fibrosis. The new structure reflects PureTech’s shift toward a ...
Business Operations and StrategyStock BuybackShareholder Meetings
PureTech Health Wins Full Shareholder Backing at 2026 AGM
Positive
Jun 10, 2026
PureTech Health plc reported that all resolutions at its 10 June 2026 Annual General Meeting were approved by shareholders, including the adoption of the 2025 annual report, the directors’ remuneration report, and the re-election or election...
Business Operations and StrategyProduct-Related Announcements
PureTech’s Seaport Unit Advances GlyphAgo After Positive Phase 1 Anxiety Drug Data
Positive
Jun 9, 2026
PureTech Health highlighted progress at its Founded Entity Seaport Therapeutics, which reported positive multiple-ascending dose data from a Phase 1 proof-of-concept trial of GlyphAgo, an oral prodrug of agomelatine designed to enhance lymphatic a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.